InfuSystem Holdings

InfuSystem Holdings

InfuSystem Holdings was incorporated in 2005 and is headquartered in Rochester Hills, Michigan, with Richard Dilorio serving as Chief Executive Officer. The company does not operate as a traditional family office or investment manager — it is a NYSE American-listed operating company (ticker: INFU) that provides ambulatory infusion pump services and related biomedical support directly to oncology clinics, hospitals, and home-care providers across the United States. The company generates revenue through a razor-and-blade model: it places infusion pumps at provider sites at little or no upfront cost, then earns recurring rental fees per pump and per disposable supply set used. Its core segment services chemotherapy infusion, while a separate pain management segment serves orthopedic and post-surgical ambulatory infusion. Payer reimbursement is managed end-to-end by InfuSystem, which handles prior authorizations, claims, and collections for the clinics — making it a turnkey revenue-cycle partner, not just a device lessor. Key operating relationships include oncology networks like the US Oncology network and pain-management practices serviced through its own direct sales force. As of its most recent annual filings, InfuSystem reported total revenues exceeding $110 million with a nationwide footprint serving thousands of clinic locations (per the firm's official communications, 2022). The company operates from facilities in Michigan, Texas, and Kansas; it centralizes biomedical repair, sterilization, and logistics from its Michigan hub. In November 2022, InfuSystem completed the acquisition of Omnicell's infusion pump service business, which expanded its installed base and added new hospital-system relationships across several states (per GlobeNewswire, November 2022). This transaction reflected an ongoing consolidation play in the outsourced biomedical services niche. The structural differentiator for InfuSystem is its dual identity as both a durable-medical-equipment provider and a revenue-cycle management company baked into one contract. Unlike pure-play device manufacturers, InfuSystem carries payer risk, invests heavily in billing infrastructure, and ties its own margin performance to the collection yield it achieves on behalf of the treating clinic — a model that creates switching costs and aligns incentives with provider partners in a way that a simple equipment lease cannot.